Hormone Therapy vs Chemotherapy — Clinical Trial Comparison
Hormone Therapy
Blocks, adds, or modifies hormones that fuel certain cancers
VS
Chemotherapy
Uses cytotoxic drugs to kill rapidly dividing cancer cells
Hormone therapy and chemotherapy are two pillars of cancer treatment that work through fundamentally different mechanisms. Hormone therapy exploits the dependence of certain cancers (breast, prostate, thyroid, ovarian) on specific hormones for growth, starving them of the hormonal signals they need. Chemotherapy attacks rapidly dividing cells directly, regardless of hormone sensitivity. Both are extensively studied in UK clinical trials, with an increasing focus on combination strategies that use both approaches together.
Key Differences at a Glance
| Feature | Hormone Therapy | Chemotherapy |
|---|---|---|
| Mechanism | Blocks hormone production or hormone receptors, depriving hormone-sensitive cancer cells of growth signals | Directly damages rapidly dividing cells (DNA damage, mitotic inhibition, antimetabolite activity) |
| Target selectivity | Highly selective — only affects hormone-dependent tissues and cancers | Non-selective — affects all rapidly dividing cells (cancer, hair, gut lining, bone marrow) |
| Route of administration | Mostly oral tablets (aromatase inhibitors, SERMs, ADT); some injections (GnRH analogues) | Usually intravenous infusion; some oral chemotherapy agents |
| Common drug types in trials | Aromatase inhibitors, SERMs/SERDs, androgen deprivation therapy, GnRH analogues, CDK4/6 inhibitors, selective androgen receptor modulators | Alkylating agents, antimetabolites, taxanes, platinum compounds, anthracyclines, vinca alkaloids |
| Treatment duration | Often 5–10 years (adjuvant setting); sometimes lifelong for metastatic disease | Usually 4–8 cycles over 3–6 months; shorter intensive courses |
| Response timing | Slower — response assessed over months, tumour shrinkage gradual | Faster — measurable response within weeks |
Clinical Trial Availability
| Trial Aspect | Hormone Therapy | Chemotherapy |
|---|---|---|
| UK trials actively recruiting | 100–180 studies | 150–250 studies |
| Most common phases | Phase 2–3 (many adjuvant and neoadjuvant) | Phase 2–3 (including neoadjuvant and metastatic) |
| Top cancers studied | Breast cancer (ER+), prostate cancer, ovarian cancer, thyroid cancer, endometrial cancer | Breast cancer, lung cancer, colorectal, ovarian, pancreatic, gastric, bladder |
| Combination trials | Hormone + CDK4/6, hormone + targeted, hormone + immuno, hormone + chemo | Chemo + targeted, chemo + immuno, chemo + hormone, chemo + radiation |
| Biomarker requirements | Hormone receptor status (ER, PR, AR) essential; BRCA, PIK3CA for some trials | Fewer biomarker requirements; some need HER2, MSI, BRCA status |
| Resistance trials | Major focus — overcoming endocrine resistance (ESR1 mutations, CDK4/6 after progression) | Fewer resistance-focused trials; more focused on optimising regimens |
Exciting Emerging Treatments
Hormone Therapy Trials
- Next-gen oral SERDs — elacestrant, amcenestrant, camizestrant improving on fulvestrant
- CDK4/6 inhibitor combinations — expanding beyond breast cancer into other solid tumours
- Novel androgen receptor degraders — PROTAC technology for treatment-resistant prostate cancer
- Hormone + immunotherapy — testing whether hormone priming enhances immune response
- Intermittent hormone therapy — cycling on/off to delay resistance and reduce side effects
- Biomarker-guided duration — using genomic tests to decide how long adjuvant hormone therapy should last
Chemotherapy Trials
- Antibody-drug conjugates (ADCs) — chemo precision-delivered via antibody targeting
- Nanoparticle drug delivery — reducing systemic toxicity through targeted packaging
- Dose-optimisation studies — finding minimum effective doses rather than maximum tolerated
- Metronomic chemotherapy — continuous low-dose scheduling with anti-angiogenic effects
- Chemo + immunotherapy priming — using chemotherapy to activate immune response before immunotherapy
- Organoid-guided therapy — testing patient-derived tumour organoids to predict chemo response
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Hormone Therapy Trial Criteria
- Hormone receptor-positive tumour (ER+ and/or PR+ for breast cancer, AR+ for prostate cancer)
- Adequate organ function (liver, kidney) — hormone drugs are metabolised hepatically
- No history of hormone-sensitive conditions that could be worsened (e.g., active DVT for SERMs)
- Bone density assessment (hormone therapy can cause bone loss)
- Pre/postmenopausal status verified (determines which hormone therapy is appropriate)
- Prior hormone therapy history (some trials require treatment-naive, others require progression on prior line)
Chemotherapy Trial Criteria
- Measurable disease per RECIST criteria
- Adequate blood counts (ANC ≥ 1.5, platelets ≥ 100, haemoglobin adequate)
- Cardiac ejection fraction within normal limits (for anthracycline trials)
- Peripheral neuropathy ≤ Grade 1 (for taxane/platinum trials)
- No uncontrolled infections or recent major surgery
- ECOG performance status 0–2
Hormone Therapy Trials
Find actively recruiting hormone therapy clinical trials across the UK
Hormone Therapy TrialsFrequently Asked Questions
Can hormone therapy and chemotherapy be used together?
Yes — combination therapy is very common in hormone-sensitive cancers. For example, breast cancer trials often test CDK4/6 inhibitors (hormone pathway) alongside aromatase inhibitors. Prostate cancer trials combine androgen deprivation therapy with chemotherapy (docetaxel) for metastatic disease. The combination approach targets cancer through multiple mechanisms simultaneously.
Is hormone therapy a milder treatment than chemotherapy?
Not necessarily milder — differently toxic. Hormone therapy side effects are often chronic rather than acute: hot flushes, bone loss, sexual dysfunction, mood changes, and increased cardiovascular risk. Chemotherapy causes more immediately visible side effects (hair loss, nausea, low blood counts) but these typically resolve after treatment ends. Hormone therapy is often taken for 5–10 years, so cumulative effects matter.
Which cancers respond to both hormone therapy and chemotherapy?
Breast cancer and prostate cancer are the most common cancers treated with both approaches. Ovarian cancer can involve hormonal strategies alongside chemotherapy. Thyroid cancer uses thyroid hormone replacement after treatment. For each cancer, the choice depends on receptor status (ER/PR/HER2 in breast, androgen sensitivity in prostate), disease stage, and prior treatments.